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Abstract 30 
Major depressive disorder (MDD) in older people is a relatively common, yet hard to treat 31 
problem.  In this study we aimed to establish if a single nucleotide polymorphism in the 5-32 
HT1A receptor gene (rs6295) determines antidepressant response in patients aged >80 33 
years (the oldest old) with MDD.   34 
Nineteen patients ≥80 years-old, with a new diagnosis of MDD were monitored for response 35 
to citalopram 20 mg daily over 4-weeks, and genotyped for the rs6295 allele. Both a 36 
frequentist and Bayesian analysis was performed on the data.  Bayesian analysis answered 37 
the clinically relevant question: ‘what is the probability that an older patient would enter 38 
remission after commencing SSRI treatment, conditional on their rs6295 genotype?’. 39 
Individuals with a CC genotype showed a significant improvement in their Geriatric 40 
Depression Score (p=0.020) and cognition (p=0.035) compared to other genotypes.  From a 41 
Bayesian perspective, we updated reports of antidepressant efficacy in older people with our 42 
data and calculated that the 4-week relative risk of entering remission, given a CC genotype, 43 
is 1.9 (95% HDI 0.7-3.5), compared to 0.52 (95% HDI 0.1-1.0) for the CG genotype.  The 44 
sample size of n=19 is too small to draw any firm conclusions, however, the data suggest a 45 
trend indicative of a relationship between the rs6295 genotype and response to citalopram in 46 
older patients, which requires further investigation. 47 
Keywords 48 
Pharmacogenomics, depression, ageing, Bayesian analyis  49 
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1 Introduction 50 
Approximately 1-4% of older adults living at home, and between 8-24% of older hospitalised 51 
inpatients are diagnosed with Major Depressive Disorder (MDD)1, a condition characterised 52 
by either depressed mood, or diminished interest or pleasure.2  Several factors, perhaps in 53 
combination, appear to contribute to the risk of developing the disorder in the elderly.  For 54 
example, previous episodes of depression, age-related neurocognitive changes, 55 
comorbidities, and the general circumstances of old age (e.g. social isolation) may interact 56 
with each other to precipitate an episode of MDD.  The symptoms of depression in later life 57 
are themselves associated with increased mortality and poor cardiovascular health.3  This is 58 
a major concern for health services around the world as the absolute numbers of older 59 
patients with MDD is set to increase as the population ages.  The need for safe, effective 60 
therapeutic interventions in this age-group is therefore of critical importance. 61 
The first-line pharmacological treatment for depression in adults and those >65 years are the 62 
selective serotonin reuptake inhibitors (SSRIs).  The rationale for using these agents is 63 
based on the serotonin hypothesis of depression first proposed by Schildkraut in 1965.4  The 64 
model has been refined in the subsequent decades but the central tenet remains that 65 
serotoninergic signalling is disrupted in the terminals of neurones projecting from the Raphé 66 
in patients suffering MDD.  A disruption to serotonergic signalling is supported by the 67 
effectiveness of SSRIs, and other antidepressants whose mode of action is through altering 68 
synaptic 5-HT levels.  Nonetheless, a proportion of patients with depression, especially 69 
those who are >65 years, appear to show less response to SSRIs (around 32-44% of older 70 
patients will reach remission on an SSRI).5,6  Several hypotheses have been proposed to 71 
explain why SSRIs lack therapeutic efficacy in some patients with MDD.  These include 72 
inter-individual differences in the pharmacokinetic profile of SSRIs, and disease aetiology.  73 
However, a major focus of research over the past 15 years has been on pharmacogenetic 74 
variation in genes which code for proteins involved in 5-HT signalling.   75 
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One key target of serotonergic signalling that is of interest is the 5-HT1A receptor.  These 76 
receptors are coupled to inhibitory G-proteins located both post-synaptically in the 77 
corticolimbic regions of the brain, and pre-synaptically, as somatodentritic autoreceptors.  78 
Their role as autoreceptors is thought to explain the 2-3 week delay in therapeutic response 79 
to SSRIs. As SSRI therapy is commenced, the increase in synaptic 5-HT concentration 80 
stimulates 5-HT1A receptors which then signal a reduction in 5-HT vesicular release, 81 
dampening any therapeutic response.  After 2-3 weeks however, 5-HT1A receptors 82 
desensitise, through a combination of internalisation and reduced expression, allowing the 83 
therapeutic activity of SSRIs to re-emerge.  However, recent studies suggest that in a small 84 
proportion of patients, response to SSRIs may be more immediate and related to a specific 85 
pharmacogenetic trait.7 86 
Because of the important role 5-HT1A receptors play in 5-HT signalling, it was thought that 87 
SNPs in the gene for this receptor may determine, at least in part, an individual’s 88 
susceptibility to SSRIs.  For example, a functional polymorphism which increases activity or 89 
expression of the receptor may reduce treatment efficacy.  Over 11 clinical trials have been 90 
conducted that have investigated the association between a common polymorphism in the 91 
promotor region of the 5-HT1A receptor gene (rs6295) that results in increased receptor 92 
expression, and treatment response.8  However, a meta-analysis which included the majority 93 
of these trials, found no overall effect of the SNP on treatment response.9 Nevertheless, it is 94 
interesting to note that in all of the trials included in the meta-analysis, only young or middle 95 
aged adults were recruited (the mean age of participants ranged from 37 to 51 years old).  96 
This is potentially important, as recent evidence suggests that the expression of pre-synaptic 97 
5-HT1A receptors decline with age.10  Therefore, in older people, the effect of the rs6295 SNP 98 
on SSRI treatment response may become more obvious, and therefore clinically relevant.  99 
For example, homozygote CC individuals, whose basal 5-HT1A expression is not up-100 
regulated, will see a decline in expression during ageing, potentially leading to a more rapid 101 
SSRI response.  Other genotypes may not see this increased response due their increased 102 
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burden of receptors.   This hypothesis is supported by data showing that the rs6295 SNP 103 
influences response in adult patients that are treated with a partial agonist of the 5-HT1A 104 
receptor (stimulating desensitisation of 5-HT1A receptors) 11.   105 
Furthermore, this decline in 5-HT1A receptor expression, coupled with the well-reported  106 
age-related decline in SERT,12 may also lead to increased serotonergic side effects, 107 
particularly in the CC genotype. To explore this further, we conducted a clinical trial to 108 
answer the question of whether the rs6295 SNP alters response to SSRI treatment 109 
(citalopram 20 mg once daily) in hospitalised patients aged >80 years old (i.e. the oldest old), 110 
who have a first diagnosis of depression on admission to hospital.   111 
We employed both a frequentist approach to answer this question, comparing mean and 112 
variance values statistically, and also a Bayesian approach, which is of increasing interest in  113 
medicine.13,14  In this paper we aim to demonstrate that both analytical methods are valid 114 
approaches in pharmacogenetic trials, but that the use of Bayesian forecasting is of 115 
particular value as it 1) unambiguously addresses the relevant clinical question at hand: is a 116 
patient more likely to enter remission following 4-weeks of SSRI treatment, than not, given 117 
knowledge of their rs6295 genotype; 2) allows future studies to add their data to ours to 118 
calculate ever-more accurate relative risk values and 3) allows a meaningful analysis of data 119 
from relatively small cohorts. 120 
 121 
122 
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2 Methods 123 
 124 
2.1 Patients and recruitment 125 
 126 
Study recruitment took place between January 2010 and January 2013 at Brighton and 127 
Sussex University Hospitals NHS Trust, UK.  To be eligible for participation in the study, 128 
participants had to meet the following inclusion/exclusion criteria and provide written 129 
informed consent: 130 
Inclusion criteria: ≥80 years old and admitted as an in-patient under the care of the elderly 131 
team; have a new clinical diagnosis of depression on admission, or during in-patient stay 132 
which required treatment with the local hospital formulary SSRI of choice, citalopram 20 mg 133 
once daily. 134 
Exclusion criteria: a current prescription for an antidepressant regardless of indication; 135 
patients lacking capacity as determined by a score of ≤7/10 on a routine Abbreviated Mental 136 
Test Score (AMTS) conducted on admission . 137 
2.2 Ethical approval 138 
 139 
Ethics approval was granted by both NHS Research Ethics Committee South-East Coast – 140 
Brighton Sussex Research Ethics Committee Reference 09/H1107/116 and the Medicines 141 
and Healthcare products Regulatatory Agency, alongside the  University of Brighton 142 
Research Ethics Committees.  The study is listed on the EU Clinical Trials Register 143 
(EudraCT number 2009-016716-20).  All experiemental procedures were conducted in 144 
accordance with HTA and Good Medical Practice regulations and guidelines. 145 
2.3 Measurement of depression and clinical status 146 
 147 
A full clinical and biochemical assessment took place at baseline, 1-week, and 4-weeks after 148 
starting SSRI treatment to determine the efficacy, tolerability and safety of citalopram 149 
therapy.  Four weeks was chosen as the temporal end-point as current UK guidelines 150 
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suggest that if no repsonse is observed at this point an increase in dose or switch to an 151 
alternative medication is required.  Measurements included: the Geriatric Depression Scale 152 
(GDS; 30/30 long form); Mini Mental State Examination Score (MMSE); Hunter Serotonin 153 
Toxicity Criteria (HSTC); urea and electrolytes; full blood count.  Remission was defined as a 154 
GDS score of ≤11 at week 4 of the study 15. 155 
2.4 Assessment of plasma citalopram levels 156 
Plasma citalopram levels were determined at 4-weeks through Enzyme-Linked 157 
ImmunoSorbant Assay (Neogen®). 158 
2.5 Assessment of platelet serotonin levels 159 
 160 
Serotonin concentrations in platelet pellets were measured using a High Performance Liquid 161 
Chromatography (HPLC) system which consisted of a Jasco HPLC pump (Model: PU-980) 162 
and Rheodyne manual injector equipped with a 20 µl loop. A Kinetic® ODS 2.6 µm 150 mm x 163 
4.6 mm i.d. analytical column with a guard column (Phenomenex®, Macclesfield, UK) was 164 
employed.  The HPLC system was run at a flow rate of 100 µL min-1. CHI630B potentiostat 165 
(CH Instruments, Austin, TX, USA) was used to control the detector voltage and record the 166 
current. A 3 mm glassy carbon electrode (flow cell, BAS) served as the working electrode 167 
and was used with a Ag|AgCl reference electrode and a stainless steel block as the auxiliary 168 
electrode. Amperometric recordings were carried out, where the working electrode was set 169 
at a potential of +950 mV vs. Ag|AgCl reference electrode. Control and data 170 
collection/processing were handled through the CHI630B software.  Briefly, 500 µl of ice cold 171 
0.1 M perchloric acid was added to the platelet pellet and samples were sonicated and 172 
vortexed for 2 minutes and then centrifuged at 14,600 x g for 10 minutes prior to 173 
chromatographic analysis. The supernatant was removed and filtered through a 0.2 µm filter 174 
and the resulting solution analysed using HPLC with electrochemical detection. 175 
 176 
 177 
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2.6 Characterisation of 5-HT1A polymorphisms 178 
 179 
DNA was extracted from 200 µl of whole blood using DNA extraction columns (DNeasy 180 
Blood and Tissue Mini-kit, Qiagen). The 5-HT1A receptor gene promotor has a SNP, rs6295, 181 
at position -1019C/G which was typed by amplification using the following primers:  forward 182 
5' TGTCGTCGTTGTTCGTTTGT 3' and reverse 5' GGTGAACAGTCCTGGGTCAG 3' 16. 183 
Amplifications were carried out in 25 µl reactions containing approximately 5 ng of DNA 184 
template and final concentrations of 15 nM 10 x reaction buffer, 1.5 mM MgCl2, 0.2 mM for 185 
each deoxynucleotide (dNTP), 10 pmol forward and reverse primers, 1 unit Platinum®Taq 186 
DNA polymerase (Invitrogen). Cycling was performed in Techne TC-4000 thermal cycler 187 
employing 40 cycles (30s at 94°C, 30s at 56°C and 60s at 72°C), with a final extension at 188 
72°C for 10 minutes. Sequencing (Sanger sequencing) procedures were performed by 189 
Source-Bioscience (Nottingham, England) to determine the nucleotide at position -1019.  190 
2.7 Frequentist analysis 191 
 192 
Chi-square tests were performed to determine the significance of any allele/genotype 193 
associations with the incidence of serotonergic side effects or the efficacy of citalopram 194 
therapy (remission, defined as a GDS score of ≤11 at week 4).   General linear regression 195 
models were fitted to estimate the relative influence of demographics and genotypes on 196 
variation in response to treatment with citalopram, and the incidence of side effects.  A one-197 
way analysis of variance with Fisher’s LSD post-hoc test was used to assess statistical 198 
significance of differences in the effects of citalopram according to genotype.  Effect size η2 199 
was calculated as the sum-of-squares
 
between groups / total sum-of-squares. To assess the 200 
statistical significance of differences in platelet [5-HT], MMSE, and GDS over time either a 201 
repeated measures one-way ANOVA, or Friedman test was used according to the 202 
distribution profile of the data.   Normality of data was tested using the Shapiro-Wilk test, 203 
where we accepted the null hypothesis that the data were normally distributed if p>0.05.  204 
Data analysis, and graphical representation, were performed in R (R Core Team, 2016) and 205 
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Graphpad Prism v6.  Statistical significance was assumed if p<0.05.  Mean ± SEM are 206 
presented unless otherwise stated. 207 
2.8 Bayesian forecasting 208 
Following the method outlined in Mould et al,18 we framed our research question in the 209 
following way: what is the conditional probability that individuals will not present in remission 210 
at week 4, i.e. a GDS of ≤11, given that they are known to have a specific genotype and that 211 
they have embarked on a course of citalopram? (The details of this approach can be found 212 
in the supplementary material).  213 
We took the odds form of Bayes’ rule: the probability of not being in remission at week 4, 214 
relative to being in remission. The appropriate prior probability distribution to employ with a 215 
likelihood that takes this form is a beta distribution 19. This distribution has two parameters, 216 
the values of which can be drawn from previously observed data relating to the unconditional 217 
probability that an older individual will go into remission following a course of citalopram. For 218 
example, the combined remission rates in 6 studies that investigated the use of citalopram in 219 
late-life depression is calculated at around 47% (n=567).20  In this scenario, the distribution 220 
is broadly described as symmetrically bell-shaped around a mean of 0.5 (corresponding to a 221 
probability of remission of 0.5). For comparison we also considered the the more 222 
conservative position that all possibilities for the probability of not responding to citalopram 223 
are equally likely, which is a specific case of the beta distribution and defines a non-224 
informative uniform distribution. 225 
To obtain the posterior distribution of the relative risk of not being in remission at week 4 226 
relative to being in remission, conditional on the genotype, we applied Gibbs sampling in 227 
order to sample from the two distributions without having to explicitly calculate the integrals. 228 
This was performed in R (R 3.2.2, 2015) using the script employed in “OPTIMISE trial in a 229 
Bayesian framework”21, which incorporates the scripts “openGraphSaveGraph.R” and 230 
“plotPost.R”.19 231 
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2.9 Data availability 232 
The datasets generated during and/or analysed during the current study are available from 233 
the corresponding author on reasonable request. 234 
3 Results 235 
3.1 Baseline demographics 236 
A total of 29 patients were enrolled into the study over a 3 year period.  Recruitment was 237 
more difficult than expected due to the population being acutely unwell.  Ten patients missed 238 
either the final, or both follow-up visits and were therefore excluded from the analysis.  The 239 
mean age of the study group was 88 ± 4 years and the mean baseline GDS for the 19 240 
patients remaining in the study was 15/30  ± 5.  The genotype frequencies of the 5-HT1A 241 
receptor was found to be 7:6:6 for CC, GC and GG respectively.  By comparing the 242 
observed genotype frequencies with the expected frequencies (5:9:4 for CC, GC and GG 243 
respectively), we were able to confirm that our sample population does not deviate, by any 244 
large extent, from Hardy-Weinberg equilibrium (Chi2 = 2.554; p = 0.5263, β-1=0.59).  A 245 
summary of the baseline demographics is shown in Table 1. 246 
3.2 Response to citalopram 247 
To measure the therapeutic effect of citalopram we compared GDS at baseline, 7 days and 248 
4 weeks for all the patients.  There was a trend towards a reduction in GDS over the 4 249 
weeks of the study, although this was not found to be statistically significant (p = 0.11, 250 
repeated measures one-way ANOVA, n=18 [1 patient did not attend the 7 day visit and so 251 
was excluded for this analysis], Fig. 1a).  A total of 8/19 patients reached remission by week 252 
4 (i.e. a GDS score of ≤1115).  Mean platelet [5-HT] reduced significantly over the duration of 253 
the study, indicating the pharmacological activity of citalopram on platelet 5-HT transporters, 254 
although we were only able to successfully measure concentrations in 7/19 participants 255 
(p<0.001, Friedman test; p<0.01 between baseline and 1 month, Dunn’s post-hoc; n=7; Fig. 256 
1b).  Mean [citalopram]plasma was 0.75 ± 0.17 mg/L. 257 
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A clinical improvement in mood has previously been associated with improved cognition in 258 
older people. 22  We did show a significant correlation between change is GDS (∆GDS) and 259 
change in MMSE (∆MMSE) over the course of the study (R2=0.27, p=0.02, Pearson’s 260 
correlation; Fig. 1c), although we were unable to detect a significant change in mean MMSE 261 
(p=0.88, Friedman Test, n=19; Fig. 1d) over the 3 visits.  262 
Treatment with citalopram has been associated with several side effects which could be 263 
particularly problematic to older patients.   Recognised complications of citalopram therapy 264 
include hyponatraemia, and gastro-intestinal bleeding as a result of depletion of platelet 5-265 
HT.  We found a small, clinically, and statistically insignificant change in plasma Na+ 266 
concentration over the duration of the study (mean plasma [Na+] = 137.6 ±1.5 vs. 135.6 ±1.2 267 
vs. 134.7 ±1.4 mmol/L at baseline, 1 week and 4 weeks respectively; (p=0.10,  repeated 268 
measures one-way ANOVA, n=16, Fig. 1e).  Plasma Hb concentration, which may fall due to 269 
gastrointestinal bleeding as a consequence of SSRI treatment did not change significantly 270 
over the course of the study (Fig. 1f).  Another rare, but serious reaction to SSRIs is 271 
serotonin syndrome.  Using the Hunter Serotonin Toxicity Criteria, one of our 19 patients 272 
was identified as positive for serotonin syndrome over the 4 week period.  273 
3.3 Factors which determine response to citalopram 274 
Despite the overall small decrease in mean GDS score over time, it is clear from the 275 
individual data that some patients responded well to citalopram, whilst others showed a 276 
continued deterioration in mood (Fig. 2a).  To explore this further, we constructed a 277 
generalised linear model to determine whether certain baseline characteristics could predict 278 
response to citalopram (i.e. absolute change in 4-week GDS).  We chose a generalised 279 
linear model due to the multinomial distribution of the data.  The first iteration of the model 280 
included 4 predictor variables (5-HT1A genotype, gender, age, and weight).  We did not 281 
include ethnicity as a variable due to only 2 of our sample being non-white.  In further 282 
iterations of the model, predictably, given the small sample size, individual variables that did 283 
not reach statistical significance were excluded until a minimum effective model was 284 
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produced 23.  The final model contained only 5-HT1A genotype as a statistically significant 285 
predictor variable, explaining 32% of the deviance in GDS score (p=0.005). 286 
3.4 The effect of 5HT1A genotype on response to citalopram 287 
To probe the role of 5-HT1A genotype in response to citalopram, we looked at the mean 288 
change in GDS over the 4-week study according to the 3 genotypes (Fig. 2b).  The mean 289 
change in GDS for the CC, GC, and GG genotypes were: -5.0 ±1.1, 1.8 ±1.3, -4.0 ±2.1 290 
(p=0.02, One-way ANOVA with Fisher’s LSD post-hoc test; n=7, 6, 6 respectively).  These 291 
data show that individuals with the GC genotype demonstrate a significantly different 292 
response to citalopram at 4-weeks compared with either CC or GG (although only individuals 293 
with a CC genotype are significantly different from 0 (single sample t-test, p<0.05)).  294 
Interestingly, individuals with a GC genotype showed a mean increase in GDS (i.e. 295 
worsening of depression), although this is not significantly different from 0.  Genotype was 296 
found to be associated with the incidence of remission at week 4 (remission/total: CC = 5/7, 297 
CG = 0/6, GG = 3/6; Chi squared test, p=0.031).    298 
We also observed a significant reduction in absolute MMSE score in patients with a GC 299 
genotype, compared to the CC group (0.4/30 ±0.7 vs. -2.3/30 ±1.0 vs. 0.3/30 ±0.5; p<0.05, 300 
One-way ANOVA,  Fisher’s LSD post-hoc test, Fig. 2c). The role of genotype on platelet [5-301 
HT] is inconclusive due to small numbers in each group (Fig. 2d).   We found no relationship 302 
between changes in plasma Na+ and Hb concentrations, or the presence of serotonin 303 
syndrome and genotype over the study period (data not shown). 304 
3.5 Relative risk of not responding to Citalopram, conditional on genotype 305 
The traditional frequentist treatment of our data presented above is indicative of an effect 306 
and, being the standard approach, is potentially of value for inter-study comparisons; 307 
however, this approach does not explicitly address the question of clinical interest.  When 308 
making a decision about starting SSRI therapy, it may be more useful for a clinician to know 309 
the probability that an individual will respond poorly to citalopram, in the knowledge of their 310 
5-HT1A genotype. Bayesian inference provides a means of addressing the former question, 311 
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and also determines the probability of our model (i.e. that there is a relationship between 312 
rs6295 genotype and response to citalopram). To perform this analysis we first categorised 313 
our participants as either responders or non-responders; where responders are those who 314 
reached remission (GDS score ≤ 11) at week 4 and non-responders are those who did not.  315 
Fig. 3 shows the influence of the prior distributions (first column) on the likelihood of each 316 
genotype (first row) in arriving at the posterior relative risk of not responding (θ1) to 317 
responding (θ2).  When an informative beta prior is considered, an individual that has the CG 318 
genotype is, on average, 1.79 times more likely to not remit at four weeks than to go into 319 
remission. The highest density interval (HDI) spans between 0.8 and 3; however, the 320 
probability that the CG individuals have a higher chance of not remitting than remitting is 321 
99.3% (proportion of the posterior distribution > θ1/ θ2 = 1).  Fig. 4 shows the relative risk of 322 
responding (θ1) to not responding (θ2).  In this analysis, when an informative prior is used, an 323 
individual that has the CC genotype is, on average, 1.9 times more likely to go into remission 324 
at four weeks than to not go into remission (Fig. 4). The HDI spans between 0.7 and 3.5, 325 
where the probability that  the CC individuals have a higher chance of going into remission 326 
than not is 93.5%.  327 
 328 
   329 
 330 
  331 
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4 Discussion 332 
4.1 Response to citalopram in the oldest old is related to 5-HT1A receptor genotype 333 
Our study set out to explore an important question relating  to the value of 5-HT1A receptor 334 
genotypes in predicting response to citalopram in the oldest old. Given the nature of our 335 
target population, recruitment was sub-optimal and our sample size is likely to be considered 336 
too small for any meaningful statistical analysis. In light of this, we wish to emphasise two 337 
key points: 1) our data are drawn from a difficult to obtain population and are likley to be of 338 
value to future studies and 2) we propose that for studies such as these, a simple Bayesian 339 
analysis is more transparent in conveying the influence of the evidence (proportional to the 340 
sample size) on any one hypothesis. 341 
The current study has shown that for a population of depressed older patients (>80 years old) 342 
genotype explains approximately 32% of the variation in response to citalopram.  We were 343 
able to exclude age, ethnicity and gender as confounders, although we acknowledge that 344 
these may have small effects that we were unable to detect with our small sample size.  345 
Other factors, which we were unable to control for may also contribute to the observed 346 
changes.  Interestingly, we showed that both homozygote groups (CC and GG) displayed a 347 
mean reduction in GDS over the study period, whilst the heterozygote group’s score 348 
increased, indicating a worsening of depression.  The calculated effect size for genotype 349 
equates to approximately 0.37 (η2), which is considered large.  The effect size of genotype 350 
on remission rates is also large (Cramer’s V=0.61), compared to similar studies conducted in 351 
younger patients (Cramer’s V=0.34), which raises the intriguing possibility that the effect of 352 
genotype is more prominent in this older population.  It should be noted however that whilst it 353 
appears that the results of GC group reflect an absence of response at 4 weeks, it may 354 
equally be the case that the response is delayed.  Conducting the study over a longer period 355 
could resolve this question, but may prove difficult due to retention issues.   356 
This non-linear relationship between the addition of a G allele on ∆GDS was not expected, 357 
yet this pattern was also observed in our analysis of genotype on MMSE following citalopram 358 
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treatment (the cognition of homozygotes both improved slightly over the course of the study, 359 
whilst the heterozygote group showed a decline). Indeed, post-hoc analysis revealed that the 360 
GC genotype behaves differently in response to citalopram compared to both homozygotes.  361 
Nonetheless, it should be noted that only the CC ∆GDS showed a statistically significant 362 
difference from 0 (p<0.05, one-sample Student’s t-test).  A similar observation was noted by 363 
Koto et al, who showed that the RS6295 heterozygote has significantly lower response and 364 
remission rates at 2 weeks compared to both homozygotes.17 365 
One possible reason for this observation could be an interaction between age and 366 
phenotype.  Evidence suggests that both 5-HT1A receptor and SERT expression decline with 367 
increasing age.10,12  The effect of the latter would be to increase synaptic 5-HT, further 368 
reducing 5-HT1A surface expression through desensitisation (internalisation and 369 
transcriptional repression).24 This may perhaps improve SSRI efficacy in CC individuals (as 370 
they would be susceptible to Deaf-1 repression), whilst having little effect on those carrying a 371 
G allele.  Our results were consistent with our hypothesis in terms of CC individuals 372 
responding positively to citalopram, and GC individuals not so; but there is an obvious 373 
conflict in the positive response observed within our GG group.  A possible explanation for 374 
this finding is summarisied in Fig. 5.  Briefly, based on previous studies, we speculate that 375 
individuals with a GG genotype in the population fall into two categories: those who have a 376 
compensatory mechanism that restores 5-HT signalling, and those who do not.  Those 377 
individuals who do not compensate will be more prone to depression, presenting with 378 
symptoms throughout life 25.  The idea of a compensatory mechanism in this genotype has 379 
been postulated previously and may involve a reduction in the expression of SERT, and a 380 
restoration of 5-HT1A expression to levels not dissimilar to other genotypes. It is these 381 
individuals which we believe may present late in life with depression, and, due to the down-382 
regulation of 5-HT1A receptors may show an uncharacteristic (based on genotype) positive 383 
response to SSRI therapy.  The situation may be complicated further by the fact that there 384 
are recognised gender differences in age-related changes to 5-HT1A expression, with 385 
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females showing less pre-synaptic receptor decline with age compared to men.26  This may 386 
potentially make aged men more sensitive to SSRIs than females.  Indeed, all males in our 387 
study (n=5) showed a reduction in GDS over the course of the study.  At this stage however, 388 
we must caution that this interpretation is speculative, but this offers a possible hypothesis 389 
that can be tested in future studies. 390 
Despite demonstrating a relationship between 5-HT1A genotype and SSRI efficacy in old age, 391 
we did not find a role for genotype in susceptibility to common adverse reactions associated 392 
with SSRIs.  Neither a reduction in plasma Na+ or Hb concentration, or the presence of 393 
serotonin syndrome were significantly different between genotypes populations, however 394 
this does not necessarily rule out a relationship as they may take a longer period to manifest 395 
than our data collection period allowed, and it may not have been possible to detect them 396 
because of our small sample size. 397 
4.2 Bayesian Analysis 398 
So far in our discussions we have considered data analysed from a frequentists viewpoint 399 
and asked the statistical question: what is the probability of observing our data if there were 400 
no underlying genotype effects.  For data where p<0.05, it is standard to consider the 401 
probability of observing our data by chance to be so small that it is more likely that there are 402 
real genotype effects.  However, with an n=19, it would be prudent to exercise some caution 403 
in drawing any firm conclusions. Furthermore, when making clinical decisions about which 404 
treatment should be initiated in an individual, this type of analysis offers little help.  Instead, it 405 
may be more useful to ask the following question: what is probability of observing treatment 406 
failure in an individual, given a particular genotyope – this approach is termed Bayesian 407 
forcasting and is arguably of more value to a clinician than frequentist data. Importantly for 408 
situations such as ours, the simple Bayesian approach we adopt at least offers a transparent 409 
indication of the contribution our evidence offers in support of any one hypothesis.   410 
The Bayesian analysis we performed incorporated data from previous studies investigating 411 
response to citalopram in older patients as the prior.  Limited as these data are for these 412 
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difficult to obtain samples, our Bayesian forcasting indicates that the CG and CC genotypes 413 
may influence response to citalopram in different directions and highlights the need for more 414 
studies in this area. Importantly, by adopting the methodology presented here, further 415 
studies can readily incorporate our posterior distributions as future priors, thereby fully 416 
benefitting from the strength Bayesian analysis brings to studies of this nature. 417 
 418 
  419 
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Baseline characteristics (n=19) 
Age (years) 88.16 (±3.8) 
Gender (male:female) 5:14 
Genotype (CC:GC:GG) 7:6:6 
CrCl (mL/min) 41.01 (±30.8) 
Weight (kg) 64.32 (±13.1) 
Baseline MMSE 27 (±2) 
Baseline GDS 15 (±5) 
Hb (g/dL) 11.97 (±2.0) 
WCC (x109/L) 9.91 (±4.7) 
Plt (x109/L) 267.16 (±91.4) 
Na (mmol/L) 138 (±6.0) 
K (mmol/L) 3.9 (±0.6) 
Urea (mmol/L) 9.2 (±3.6) 
Ethnicity White British 17 
Mixed White and Black African 2 
 517 
Table 1. Demographic and clinical data of study recruitments. Values represent mean ± 518 
standard deviation (with the exception of gender and genotype). 519 
  520 
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Fig. 1 Effect of citalopram on clinical and psychological measure.  (a) There is small but 521 
statistically insignificant reduction in GDS over the 1 month study.  (b) Platelet [5-HT] shows 522 
a significant reduction of the study period (n=7, p<0.01, Friedman Test).  (c) There is 523 
significant correlation between the change in GDS during treatment and MMSE, although 524 
mean MMSE remains stable over the study period (d; n=19, R2=0.27, p=0.02, Pearson’s 525 
correlation).  (e) and (f) Both plasma Na and Hb concentrations remained stable over the 526 
study period respectively 527 
 528 
Fig. 2 The relationship between 5-HT1A genotype and response to citalopram.  (a) Histogram 529 
demonstrating the distribution of partipants ∆GDS scores.  The appears to be 3 groups of 530 
patients: a group of responders, a group demonstrating no clinical change, and a group 531 
whose depression score declines. (b) Individuals with GC genotype were significantly 532 
different to indiviuals with a CC genotype in terms of effect on depression score (GDS; n=19, 533 
p=0.024, one-way ANOVA).  (c) Individuals with GC genoype showed a significant decrease 534 
in cognition over the study period compared with CC and GG genotype (n=19, p=0.035, one-535 
way ANOVA). (d) No statistically significant difference was found between the 3 genotypes 536 
in terms of platelet [5-HT] concentration 537 
 538 
Fig. 3 The histograms show the posterior relative risk of not responding (θ1), relative to 539 
responding (θ2), conditional upon genotype using a non-informative, uniform prior (beta(1,1)), 540 
and a prior that corresponds to the literature but with a reasonable degree of uncertainty 541 
(beta(4,4))(first column). The first row gives the The likelihoods of the not-responding group 542 
for each genotype (D = data). Black horizontal bars represent 95% highest density intervals 543 
(95% chance that the true relative risk falls within this interval). Note the variable scale on 544 
the x-axis. 545 
 546 
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Fig. 4 The histograms show the posterior relative risk of responding (θ1), relative to not 547 
responding (θ2), conditional upon genotype using a non-informative, uniform prior (beta(1,1)), 548 
and an informative prior (beta(4,4))(first column). The first row gives the The likelihoods of 549 
the not responding group for each genotype (D =data). Black horizontal bars represent 95% 550 
highest density intervals (95% chance that the true relative risk falls within this interval). Note 551 
the variable scale on the x-axis.  552 
 553 
Fig. 5 Proposed mechanism to explain unexpected positive response of GG individuals to 554 
citalopram.  The GG genotype has been postulated to comprise two sets of individuals, 555 
those who posess a compensatory mechanism to restore 5-HT signalling, and those who do 556 
not.  It might be expected that GG individuals without a compensatory mechasim will be 557 
prone to depression throughout life and require antidepressant therapy during adulthood.  In 558 
this study we propose that it is GG individuals who have a compensatory mechanism that 559 
present in old age with depression that requires treatment.  Due to the down-regulation of 5-560 
HT1A receptors, these individuals may be expected to respond well to SSRI therapy. 561 
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Fig. 3 The histograms show the posterior relative risk of not responding (θ1), relative to responding (θ2), 
conditional upon genotype using a non-informative, uniform prior (beta(1,1)), and a prior that corresponds 
to the literature but with a reasonable degree of uncertainty (beta(4,4))(first column). The first row gives 
the The likelihoods of the not-responding group for each genotype (D = data). Black horizontal bars 
represent 95% highest density intervals (95% chance that the true relative risk falls within this interval.  
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Fig. 4 The histograms show the posterior relative risk of responding (θ1), relative to not responding (θ2), 
conditional upon genotype using a non-informative, uniform prior (beta(1,1)), and an informative prior 
(beta(4,4))(first column). The first row gives the The likelihoods of the not responding group for each 
genotype (D =data). Black horizontal bars represent 95% highest density intervals (95% chance that the 
true relative risk falls within this interval.  
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Fig. 5 Proposed mechanism to explain unexpected positive response of GG individuals to citalopram.  The 
GG genotype has been postulated to comprise two sets of individuals, those who posess a compensatory 
mechanism to restore 5-HT signalling, and those who do not.  It might be expected that GG individuals 
without a compensatory mechasim will be prone to depression throughout life and require antidepressant 
therapy during adulthood.  In this study we propose that it is GG individuals who have a compensatory 
mechanism that present in old age with depression that requires treatment.  Due to the down-regulation of 
5-HT1A receptors, these individuals may be expected to respond well to SSRI therapy.  
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Supplementary material 
 
 
Bayesian forecasting 
A major part of this study examined whether 5-HT1A receptor genotype affects the efficacy 
of citalopram in the oldest old. Following the method outlined in Mould et al (1), this question 
was framed as follows.  Given that individuals have a particular genotype at the C1019G 
locus, what is the probability that they will or will not be in remission by week 4 of treatment 
with citalopram (i.e. a GDS of ≤11)?  We can, for example, formulate our question as the 
conditional probability that individuals will not present in remission at week 4 (), given that 
they are known to have a specific genotype (G) and that they have embarked on a course of 
citalopram (C).  This conditional probability has the notation Pr(|G,C). This probability can 
be calculated using Bayes’ rule, generally: 
| 	
 
| 	
 |	

|	

 
Giving: 
| 
 
| 
 |

|

 
If we take the odds form of Bayes’ rule, the probability of not being in remssion at week 4, 
relative to being in remission is calculated as follows: 
|

		|


|
|

|
|

        (1) 
Where Pr(G| ) is the likelihood function for the current genotypic data and Pr(|) the 
prior probability of individuals not being in remission when given a course of citalopram. 
Because our outcome is binary (no remission/remission), we can characterize our likelihood 
as a binomial distribution: 
Pr(G|) ∝         (2) 
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If, for example, we specify that our genotype of interest is the CG heterozygote, then x is the 
number of CG (“successes”), n the total sample size and R (= 1 - ) is the probability of 
positively responding to citalopram (i.e. remission). The appropriate prior probability 
distribution to employ with a likelihood that takes this form is a beta distribution (2). This 
distribution has two parameters (a and b) and the probability density is defined as:  
Pr( |a, b) =        
 (3) 
The values of a and b that define this distribution can be drawn from previously observed 
data relating to the unconditional probability that an older individual will go into remission 
following a course of citalopram.  For example, the combined remission rates in 6 studies 
investigating the use of citalopram in late-life depression is calculated at around 47% 
(n=567) (3).  In this scenario, a ≈ b. For example, where a = b = 4, the distribution is broadly 
described as symmetrically bell-shaped around a mean of 0.5 (corresponding to a probability 
of remission of 0.5), but where probabilities of 0.2 and 0.8 are not unreasonable. If no useful 
data can be obtained, we take the position that all possibilities for Pr() are equally likely, 
which is a specific case of the beta distribution (a = b = 1) and defines a non-informative 
uniform distribution.       
To obtain the posterior distribution of relative risk (Pr(|CG, C) / Pr(R|CG, C), eq (1)) we 
applied Gibbs sampling in order to sample from the two distributions (Pr(|CG, C) and 
Pr(R|CG, C)), without having to explicitly calculate the integrals. This was performed in R (R 
3.2.2, 2015) using the script employed in “OPTIMISE trial in a Bayesian framework” (4), 
which incorporates the scripts “openGraphSaveGraph.R” and “plotPost.R” (2). 
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